Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers

• 主要な著者: Desmond Y. H. Yap (著者), Jojo Hai (著者), Paul C. H. Lee (著者), Xueying Zhou (著者), Michael Lee (著者), Yu Zhang (著者), Meng Wang (著者), Xiaoxiang Chen (著者)
• フォーマット: 図書
• 出版事項: Wiley, 2021-09-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Abstract Blockade of the binding between neonatal Fc receptor and IgG‐Fc reduces circulating IgG, and thus emerges as a potential therapy for IgG‐mediated autoimmune conditions. This was a double blind, randomized, single ascending dose study to evaluate the safety, pharmacokinetics, and pharmacodyn...